Effectiveness of inhibitor rapamycin, saracatinib, linsitinib and JNJ-38877605 against human prostate cancer cells.

Wenzhi Li(Shanghai Ninth People's Hospital), Gang Chen(Fudan University), Fengfu Guo(Linyi People's Hospital), Zhanyu Wang(Jinshan Hospital of Fudan University), Hongjun Liu(Jiaxing University), Zhong Wang(Shanghai Ninth People's Hospital), Xiangfei He(Linyi People's Hospital), Longmei Wang(Linyi People's Hospital), Guangjian Wang(Linyi People's Hospital)
PubMed
January 1, 2015
Cited by 10

Related Papers

Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
|PubMed|2001|861
FDA Drug Approval Summary: Gefitinib (ZD1839) (Iressa®) Tablets
|The Oncologist|2003|576
Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.
|PubMed|2002|469
miR-146a Inhibits Cell Growth, Cell Migration and Induces Apoptosis in Non-Small Cell Lung Cancer Cells
|PLoS ONE|2013|267
The structure of the C‐terminal actin‐binding domain of talin
|The EMBO Journal|2007|205